Algernon Pharmaceuticals Inc. C.AGN

Aug. 05, 2020 the first patient was dosed.

[B52paul]

the first patient was dosed in its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil)

The patient was enrolled and dosed at the Waikato Hospital located in Hampton, New Zealand.

https://www.globenewswire.com/news-release/2020/08/05/2073308/0/en/Algernon-Announces-First-Patient-Dosed-in-Phase-2-IPF-and-Chronic-Cough-Human-Trial-of-Ifenprodil.html

Ifenprodil showed very promising results in our IPF and cough pre-clinical studies and so I am very pleased to announce our first patient in and the formal start of our clinical program,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “As the study progresses, the Company will make an assessment of the enrollment rate and will provide an update to the market on a projected completion date as well as when the data will be expected.”

[Algernon]

This post has been removed in accordance with Community Policy

[TheBearInTheWoods]

There is a very simple answer, rather the team is waiting for a very specific type of patient or the doctors on the ground aren't seeing any type of results and have not been giving the drug. Fast trials aren't successful and doctors don't waste their time giving drugs that aren't working. 

[MoneyTalks22]

yes this is correct and the CEO also stated that they decided to open up the age range for those who qualify so they can meet the number of patients required for the trial... 

[TheBearInTheWoods]

That is a terrible sign from the CEO imho